CN1622958B - 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体 - Google Patents

促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体 Download PDF

Info

Publication number
CN1622958B
CN1622958B CN028164229A CN02816422A CN1622958B CN 1622958 B CN1622958 B CN 1622958B CN 028164229 A CN028164229 A CN 028164229A CN 02816422 A CN02816422 A CN 02816422A CN 1622958 B CN1622958 B CN 1622958B
Authority
CN
China
Prior art keywords
tsh receptor
tsh
amino acids
receptor
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN028164229A
Other languages
English (en)
Chinese (zh)
Other versions
CN1622958A (zh
Inventor
伯纳德·里斯·史密斯
雅德维加·富尔马尼亚克
简·菲娜·桑德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RSR Ltd
Original Assignee
RSR Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120649A external-priority patent/GB0120649D0/en
Priority claimed from GB0215212A external-priority patent/GB0215212D0/en
Application filed by RSR Ltd filed Critical RSR Ltd
Priority to CN201310075812.8A priority Critical patent/CN103224562B/zh
Publication of CN1622958A publication Critical patent/CN1622958A/zh
Application granted granted Critical
Publication of CN1622958B publication Critical patent/CN1622958B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
CN028164229A 2001-08-23 2002-08-21 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体 Expired - Lifetime CN1622958B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310075812.8A CN103224562B (zh) 2001-08-23 2002-08-21 促甲状腺素受体的表位区域和针对该区域的抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0120649A GB0120649D0 (en) 2001-08-23 2001-08-23 Epitope regions of a thyrotrophin (TSH) receptor and uses thereof
GB0120649.9 2001-08-23
GB0215212.2 2002-07-01
GB0215212A GB0215212D0 (en) 2002-07-01 2002-07-01 Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
PCT/GB2002/003831 WO2003018632A2 (en) 2001-08-23 2002-08-21 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201310075812.8A Division CN103224562B (zh) 2001-08-23 2002-08-21 促甲状腺素受体的表位区域和针对该区域的抗体
CN2010101273436A Division CN101799476B (zh) 2001-08-23 2002-08-21 筛选针对tsh受体的自身抗体的试剂盒

Publications (2)

Publication Number Publication Date
CN1622958A CN1622958A (zh) 2005-06-01
CN1622958B true CN1622958B (zh) 2013-04-03

Family

ID=26246470

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010101273436A Expired - Lifetime CN101799476B (zh) 2001-08-23 2002-08-21 筛选针对tsh受体的自身抗体的试剂盒
CN201310075812.8A Expired - Lifetime CN103224562B (zh) 2001-08-23 2002-08-21 促甲状腺素受体的表位区域和针对该区域的抗体
CN028164229A Expired - Lifetime CN1622958B (zh) 2001-08-23 2002-08-21 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN2010101273436A Expired - Lifetime CN101799476B (zh) 2001-08-23 2002-08-21 筛选针对tsh受体的自身抗体的试剂盒
CN201310075812.8A Expired - Lifetime CN103224562B (zh) 2001-08-23 2002-08-21 促甲状腺素受体的表位区域和针对该区域的抗体

Country Status (6)

Country Link
US (4) US8298769B2 (OSRAM)
EP (3) EP1456234B1 (OSRAM)
JP (2) JP2005509412A (OSRAM)
CN (3) CN101799476B (OSRAM)
ES (3) ES2732276T3 (OSRAM)
WO (1) WO2003018632A2 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101799476B (zh) 2001-08-23 2013-01-02 Rsr有限公司 筛选针对tsh受体的自身抗体的试剂盒
JP5314234B2 (ja) * 2002-11-29 2013-10-16 アールエスアール リミテッド チロトロピン受容体の結合対象及びその使用
EP1612224B1 (en) 2004-06-29 2012-03-07 B.R.A.H.M.S GmbH Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
GB0418181D0 (en) 2004-08-13 2004-09-15 Rsr Ltd Thyrotrophin receptor preparations,thyrotrophin receptor epitopes,antibody and hormone interactions therewith,and uses thereof
WO2007057778A2 (en) * 2005-11-21 2007-05-24 Dr. Fenning Biomed Gmbh Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against tsh receptor
JP5165672B2 (ja) * 2006-03-29 2013-03-21 キングス カレッジ ロンドン Ｔｓｈｒに対するアゴニスト抗体
ES2550158T3 (es) * 2007-08-06 2015-11-04 Chugai Seiyaku Kabushiki Kaisha Método para medir la actividad inhibidora sobre la unión ligando-receptor
EP2617735A3 (en) * 2008-12-24 2013-10-16 Rsr Limited Human anti tshr antibodies
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
KR102585625B1 (ko) * 2014-12-24 2023-10-05 아피토프 인터내셔날 엔브이 조성물
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
EP3380620B1 (en) 2015-11-23 2024-07-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
CN109072195A (zh) 2015-12-30 2018-12-21 诺华股份有限公司 具有增强功效的免疫效应细胞疗法
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
AU2018355427A1 (en) 2017-10-25 2020-04-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US12441815B2 (en) 2018-11-02 2025-10-14 The Regents Of The University Of California Compositions and methods for diagnosis of cardiovascular disease
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220116522A (ko) 2019-12-20 2022-08-23 노파르티스 아게 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
KR20250057832A (ko) * 2022-08-31 2025-04-29 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005345A1 (en) * 1998-07-21 2000-02-03 Basil Rapoport Human thyrotropin receptor compositions and use thereof
EP1078986A2 (en) * 1999-08-24 2001-02-28 Tosoh Corporation Secretory thyroid stimulating hormone receptor (TSHR), and method for assaying anti-TSHR antibody using the same

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244940A (en) 1978-09-05 1981-01-13 Bio-Rad Laboratories, Inc. Single-incubation two-site immunoassay
US4514498A (en) 1982-05-26 1985-04-30 The Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Treponema
US4472508A (en) 1982-12-30 1984-09-18 The Beth Israel Hospital Association Test for detecting and measuring the graves' disease-specific immunoglobulins
WO1984003106A1 (en) 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
US4609622A (en) 1983-05-31 1986-09-02 Interthyr Research Foundation Inc. Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4661446A (en) 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
WO1990008528A1 (en) 1989-01-11 1990-08-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce Biologically active synthetic thyrotropin and cloned gene for producing same
DK0614975T3 (da) 1989-05-05 2002-11-11 Genentech Inc Glycoproteinhormonreceptormolekyler
US6261800B1 (en) 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
US5614363A (en) 1990-01-25 1997-03-25 New England Medical Center Hospitals, Inc. TSH receptor
US5744348A (en) 1989-09-08 1998-04-28 New England Medical Center Hospitals, Inc. TSH receptor
DE68927461T2 (de) * 1989-12-14 1997-03-20 B.R.A.H.M.S Diagnostica Gmbh, 12099 Berlin Polypeptide mit Thyrotropinrezeptor-Aktivität, kodierende Nukleinsäuresequenzen für solche Rezeptoren und Verwendung dieser Polypeptide
WO1991009137A1 (en) 1989-12-20 1991-06-27 Basil Rapoport Recombinant thyrotropin receptor
JPH04149197A (ja) * 1990-10-12 1992-05-22 Tanabe Seiyaku Co Ltd 新規ペプチド
EP0482598A3 (en) 1990-10-24 1993-05-19 Ishihara Sangyo Kaisha, Ltd. Peptide analog of human tsh receptor affective against autoimmune hyperthyroidism
US5578496A (en) 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
AU679439B2 (en) 1992-02-10 1997-07-03 Duke University Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens
US5705400A (en) 1992-03-07 1998-01-06 Rsr Limited Assay for adrenal autoantigen
US5195860A (en) 1992-07-20 1993-03-23 Trw Inc. Push-on type fastener for automatic feed and installation equipment
JPH06220089A (ja) * 1993-01-27 1994-08-09 Ishihara Sangyo Kaisha Ltd ペプチド又はその塩並びにそれらを含有する自己免疫性甲状腺疾患の診断薬又は治療薬
WO1994018566A1 (fr) 1993-02-04 1994-08-18 Sumitomo Pharmaceuticals Company, Limited Procede de dosage d'un anticorps specifique
DE4328070C1 (de) 1993-08-20 1994-11-24 Henning Berlin Gmbh Verfahren zur Bestimmung eines Analyten in einem Volumen einer flüssigen Probe sowie seine Anwendung zur Bestimmung von anti-TSH-Rezeptor-Autoantikörpern in einem Patientenserum
JPH0789991A (ja) * 1993-09-28 1995-04-04 Mitsubishi Chem Corp 新規なポリペプチドおよびそれを用いるｔｓｈ受容体抗体の測定法
EP0719858A3 (en) 1994-12-27 1997-12-29 Tosoh Corporation Myeloma cell line expressing recombinant human thyroid stimulating hormone receptor
DE19505266C1 (de) 1995-02-16 1996-10-02 Brahms Diagnostica Gmbh Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren
DE19522171C1 (de) 1995-06-19 1996-08-22 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Anti-TSH-Rezeptor-Autoantikörpern
US5723343A (en) 1995-08-28 1998-03-03 University Of Florida Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor
DE19728991A1 (de) 1996-11-06 1999-02-11 Brahms Diagnostica Gmbh Rezeptorbindungsassay, für den Rezeptorbindungsassay geeigneter rekombinanter Fusionsrezeptor, Vektor zu dessen Herstellung sowie Reagenziensatz für die Durchführung des Rezeptorbindungsassays
US5734464A (en) 1996-11-06 1998-03-31 Cobe Laboratories, Inc. Red blood cell spillover detection technique
US6692625B1 (en) 1996-11-06 2004-02-17 Robert Bosch Gmbh Electrochemical sensor
DE19651093C2 (de) * 1996-12-09 1999-06-10 Brahms Diagnostica Gmbh Rezeptorbindungsassay zum Nachweis von TSH-Rezeptor-Autoantikörpern sowie Reagenziensatz für die Durchführung eines solchen Rezeptorbindungsassays
IL123888A0 (en) 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
GB9909661D0 (en) * 1998-06-06 1999-06-23 Rsr Ltd Assays for TSH receptor autoantibodies
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP4427878B2 (ja) * 1999-08-20 2010-03-10 味の素株式会社 析出を伴う発酵法によるｌ−グルタミン酸の製造法
ES2248133T3 (es) 1999-10-12 2006-03-16 Ulrich Loos Procedimiento para la determinacion de autoanticuerpos contra el receptor de tsh.
WO2001044300A2 (en) 1999-12-13 2001-06-21 Cambridge Antibody Technology Limited Brain specific binding members
DE50106201D1 (de) 2000-02-21 2005-06-16 Brahms Ag Verfahren zur differentialdiagnostischen bestimmung von gegen den tsh-rezeptor gebildeten autoantikörpern in einer serum- oder plasmaprobe eines patienten
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
DE10126968A1 (de) 2001-06-01 2002-12-12 Ivoclar Vivadent Ag Farbstoffzusammensetzung zum individuellen Einfärben von Prothesenkunststoffen
CN101799476B (zh) 2001-08-23 2013-01-02 Rsr有限公司 筛选针对tsh受体的自身抗体的试剂盒
JP5314234B2 (ja) 2002-11-29 2013-10-16 アールエスアール リミテッド チロトロピン受容体の結合対象及びその使用
US8840891B2 (en) * 2007-02-15 2014-09-23 Rsr Limited Human monoclonal antibodies to the thyrotropin receptor which act as antagonists
EP2617735A3 (en) * 2008-12-24 2013-10-16 Rsr Limited Human anti tshr antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005345A1 (en) * 1998-07-21 2000-02-03 Basil Rapoport Human thyrotropin receptor compositions and use thereof
EP1078986A2 (en) * 1999-08-24 2001-02-28 Tosoh Corporation Secretory thyroid stimulating hormone receptor (TSHR), and method for assaying anti-TSHR antibody using the same

Also Published As

Publication number Publication date
US8298771B2 (en) 2012-10-30
US8298769B2 (en) 2012-10-30
EP2383290B1 (en) 2019-05-08
US9751940B2 (en) 2017-09-05
WO2003018632A2 (en) 2003-03-06
EP1456234A2 (en) 2004-09-15
US20090202438A1 (en) 2009-08-13
ES2736165T3 (es) 2019-12-26
JP2005509412A (ja) 2005-04-14
US20090203036A1 (en) 2009-08-13
US20130089561A1 (en) 2013-04-11
CN101799476B (zh) 2013-01-02
WO2003018632A3 (en) 2004-06-17
EP2383291A2 (en) 2011-11-02
EP2383290A2 (en) 2011-11-02
ES2732276T3 (es) 2019-11-21
EP1456234B1 (en) 2014-04-09
CN103224562A (zh) 2013-07-31
CN103224562B (zh) 2017-09-08
ES2466377T3 (es) 2014-06-10
JP5576072B2 (ja) 2014-08-20
EP2383290A3 (en) 2012-10-10
EP2383291B1 (en) 2019-04-17
CN1622958A (zh) 2005-06-01
CN101799476A (zh) 2010-08-11
US8309693B2 (en) 2012-11-13
EP2383291A3 (en) 2013-02-13
US20050118638A1 (en) 2005-06-02
JP2009278998A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
CN1622958B (zh) 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体
JP2009278998A5 (OSRAM)
US8298770B2 (en) Methods, kits, and antibodies for detecting parathyroid hormone
EA023406B1 (ru) Антитела к гепцидину и варианты их применения
KR20220122467A (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
JP2729159B2 (ja) ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
Seetharamaiah et al. Generation and characterization of monoclonal antibodies to the human thyrotropin (TSH) receptor: antibodies can bind to discrete conformational or linear epitopes and block TSH binding
EP2121758B1 (en) Human monoclonal antibodies to the thyrotropin receptor which act as antagonists
TW202342102A (zh) 治療兒科病症之方法
JP4980901B2 (ja) 新規なモノクローナル甲状腺刺激または阻害抗体、その可変領域に相当するペプチド配列、ならびに診断用医薬、予防用医薬および治療用医薬におけるそれらの使用
JP5345556B2 (ja) アンタゴニストとして作用する、サイロトロピンレセプターに対するヒトモノクローナル抗体
AU606972B2 (en) Method and compositions for making acsf and acsf antagonists
JP3894381B2 (ja) 抗Ｇｌｕ▲１７▼−オステオカルシン抗体
Hayakawa et al. Isolation and characterization of human monoclonal autoantibodies to glutamic acid decarboxylase
EP1688434A1 (en) Antibody and use of the same
MATSUI et al. Biological activities of rat antisera raised against synthetic peptides of human thyrotropin receptor
JP2007045834A (ja) 抗Ｇｌｕ１７−オステオカルシン抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20130403

CX01 Expiry of patent term